Streetbeat News

Analyst Ratings

BKKT

Rosenblatt analyst Andrew Bond has reiterated a Buy rating on Bakkt Holdings (NYSE:BKKT) and maintained a price target of $0.75.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:13 pm

HSY

Exane BNP Paribas analyst Max Gumport downgraded Hershey (HSY) from Outperform to Neutral and set a price target of $208.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:08 pm

DYN

Oppenheimer analyst Francois Brisebois reiterates an Outperform rating on Dyne Therapeutics (NASDAQ:DYN) and maintains a $47 price target.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:07 pm

ADUS

Oppenheimer analyst Michael Wiederhorn has maintained an Outperform rating on Addus HomeCare (NASDAQ:ADUS) and kept the price target at $118.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:05 pm

PENN

PENN Entertainment's stock is trading higher following Mizuho's initiation of coverage with a Buy rating and a $29 price target.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:04 pm

RDVT

B. Riley Securities analyst Josh Nichols initiates coverage on Red Violet (NASDAQ:RDVT) with a Buy rating and a price target of $25.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:03 pm

HARP

Oppenheimer analyst Hartaj Singh maintains an Outperform rating on Harpoon Therapeutics (NASDAQ:HARP), indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:03 pm

RDDT

New Street Research analyst Dan Salmon initiates coverage on Reddit (NYSE:RDDT) with a Neutral rating and a price target of $54.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 2:01 pm

REGN

Analysts have provided diverse opinions on Regeneron Pharmaceuticals (NASDAQ:REGN) with a mix of bullish to bearish ratings over the past quarter. The average 12-month price target for REGN has been raised to $1068.58, indicating a positive outlook. The company's financials show a market capitalization above industry average, but it lags in revenue growth, net margin, ROE, and ROA compared to its peers. However, its low debt-to-equity ratio is seen positively.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 2:01 pm

MAA

Mid-America Apartment (NYSE:MAA) received mixed ratings from 10 analysts, with a majority being indifferent. The average 12-month price target is set at $139.25, showing a slight increase from the previous target. Analyst actions include maintaining, lowering, and raising ratings and price targets, reflecting their response to market conditions and company performance. MAA, a REIT focusing on multifamily apartment communities, shows strong financial metrics such as revenue growth, net margin, ROE, and ROA, outperforming industry standards.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 2:01 pm